These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

495 related items for PubMed ID: 28792132

  • 1. Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib.
    Kang D, Han Z, Oh GH, Joo Y, Choi HJ, Song JJ.
    Yonsei Med J; 2017 Sep; 58(5):899-909. PubMed ID: 28792132
    [Abstract] [Full Text] [Related]

  • 2. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y, Zheng T, Song R, Wang J, Yin D, Wang L, Liu H, Tian L, Fang X, Meng X, Jiang H, Liu J, Liu L.
    Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
    Zhai B, Zhang X, Sun B, Cao L, Zhao L, Li J, Ge N, Chen L, Qian H, Yin Z.
    Tumour Biol; 2016 Jun; 37(6):8047-55. PubMed ID: 26711788
    [Abstract] [Full Text] [Related]

  • 5. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P, Li H, Jiang X, Zhai B, Tan G, Zhao D, Qiao H, Liu B, Jiang H, Sun X.
    Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
    [Abstract] [Full Text] [Related]

  • 6. High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo.
    Xiao Y, Sun L, Fu Y, Huang Y, Zhou R, Hu X, Zhou P, Quan J, Li N, Fan XG.
    BMC Cancer; 2017 Dec 15; 17(1):857. PubMed ID: 29246127
    [Abstract] [Full Text] [Related]

  • 7. Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal.
    Wang Q, Yu T, Yuan Y, Zhuang H, Wang Z, Liu X, Feng M.
    J Surg Oncol; 2013 Mar 15; 107(4):422-7. PubMed ID: 22833259
    [Abstract] [Full Text] [Related]

  • 8. LB-100 sensitizes hepatocellular carcinoma cells to the effects of sorafenib during hypoxia by activation of Smad3 phosphorylation.
    Fu QH, Zhang Q, Zhang JY, Sun X, Lou Y, Li GG, Chen ZL, Bai XL, Liang TB.
    Tumour Biol; 2016 Jun 15; 37(6):7277-86. PubMed ID: 26666823
    [Abstract] [Full Text] [Related]

  • 9. A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells.
    Fernando J, Malfettone A, Cepeda EB, Vilarrasa-Blasi R, Bertran E, Raimondi G, Fabra À, Alvarez-Barrientos A, Fernández-Salguero P, Fernández-Rodríguez CM, Giannelli G, Sancho P, Fabregat I.
    Int J Cancer; 2015 Feb 15; 136(4):E161-72. PubMed ID: 25053293
    [Abstract] [Full Text] [Related]

  • 10. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
    Qu Z, Wu J, Wu J, Luo D, Jiang C, Ding Y.
    J Exp Clin Cancer Res; 2016 Sep 30; 35(1):159. PubMed ID: 27716356
    [Abstract] [Full Text] [Related]

  • 11. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer.
    Xia H, Ooi LL, Hui KM.
    Hepatology; 2013 Aug 30; 58(2):629-41. PubMed ID: 23471579
    [Abstract] [Full Text] [Related]

  • 12. PPARδ Reprograms Glutamine Metabolism in Sorafenib-Resistant HCC.
    Kim MJ, Choi YK, Park SY, Jang SY, Lee JY, Ham HJ, Kim BG, Jeon HJ, Kim JH, Kim JG, Lee IK, Park KG.
    Mol Cancer Res; 2017 Sep 30; 15(9):1230-1242. PubMed ID: 28584024
    [Abstract] [Full Text] [Related]

  • 13. An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells.
    Tang S, Tan G, Jiang X, Han P, Zhai B, Dong X, Qiao H, Jiang H, Sun X.
    Oncotarget; 2016 Nov 08; 7(45):73257-73269. PubMed ID: 27689326
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
    Lin HH, Feng WC, Lu LC, Shao YY, Hsu CH, Cheng AL.
    Cancer Lett; 2016 Oct 10; 381(1):58-66. PubMed ID: 27431312
    [Abstract] [Full Text] [Related]

  • 15. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I, Pinyol R, Dauch D, Torrecilla S, Tovar V, Moeini A, Alsinet C, Portela A, Rodriguez-Carunchio L, Solé M, Lujambio A, Villanueva A, Thung S, Esteller M, Zender L, Llovet JM.
    Gastroenterology; 2016 Dec 10; 151(6):1192-1205. PubMed ID: 27614046
    [Abstract] [Full Text] [Related]

  • 16. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S, Sun X.
    Oncotarget; 2015 Oct 06; 6(30):28867-81. PubMed ID: 26311740
    [Abstract] [Full Text] [Related]

  • 17. Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway.
    Ou DL, Lee BS, Chang YC, Lin LI, Liou JY, Hsu C, Cheng AL.
    PLoS One; 2013 Oct 06; 8(6):e66589. PubMed ID: 23818948
    [Abstract] [Full Text] [Related]

  • 18. Role of sirtuin 1 (SIRT1) in regulation of autophagy and nuclear factor-kappa Beta (NF-ĸβ) pathways in sorafenib-resistant hepatocellular carcinoma (HCC).
    Chan HY, Ramasamy TS, Chung FF, Teow SY.
    Cell Biochem Biophys; 2024 Jun 06; 82(2):959-968. PubMed ID: 38466472
    [Abstract] [Full Text] [Related]

  • 19. Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint.
    Chen J, Ji T, Zhao J, Li G, Zhang J, Jin R, Liu J, Liu X, Liang X, Huang D, Xie A, Lin H, Cang Y, Cai X.
    Oncotarget; 2016 Jul 05; 7(27):41274-41284. PubMed ID: 27129180
    [Abstract] [Full Text] [Related]

  • 20. Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.
    Tovar V, Cornella H, Moeini A, Vidal S, Hoshida Y, Sia D, Peix J, Cabellos L, Alsinet C, Torrecilla S, Martinez-Quetglas I, Lozano JJ, Desbois-Mouthon C, Solé M, Domingo-Domenech J, Villanueva A, Llovet JM.
    Gut; 2017 Mar 05; 66(3):530-540. PubMed ID: 26658144
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.